MedTrace Logo

To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment

NCT06500494 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 368

Last updated 2025-07-24

No results posted yet for this study

Summary

This study looks at how well oral vinorelbine works in treating advanced breast cancer. It looks at women who have already had this treatment or are currently having it.

Conditions

Interventions

DRUG

Vinorelbine Tartrate Oral

The recommended dosage for oral vinorelbine is 60 mg/m² of body surface area (BSA) administered once weekly for the first three weeks, followed by 80 mg/m² of BSA for the following weekly administration.

Sponsors & Collaborators

  • Pierre Fabre Medicament

    lead INDUSTRY

Principal Investigators

  • Eric Garrigue, MD · Pierre Fabre Medicament

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-10
Primary Completion
2028-02-29
Completion
2028-02-29

Countries

  • Algeria
  • China
  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06500494 on ClinicalTrials.gov